BCM
BCRX icon

Bridgeway Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bridgeway Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-32,764
Closed -$418K – 1472
2014
Q2 		$418K Buy
32,764
+1,100
+3% +$10.7K 0.01% 1166
2014
Q1 		$335K Hold
31,664
– – 0.01% 1216
2013
Q4 		$241K Hold
31,664
– – 0.01% 1261
2013
Q3 		$231K Buy
+31,664
New +$161K 0.01% 1285

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Bridgeway Capital Management's BCRX Position: Q3 2014 in Review

Bridgeway Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2014, closing a stake of 32,764 shares — an estimated $418K sold.

Bridgeway Capital Management first reported a position in BCRX in Q3 2013 and held it in 4 quarters. The position peaked at $418K in Q2 2014. 102 funds tracked by Wall St. Rank hold BCRX as of Q3 2014.

  • Bridgeway Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Bridgeway Capital Management sold 32,764 BioCryst Pharmaceuticals shares in Q3 2014, an estimated $418K.
  • Bridgeway Capital Management first reported a position in BioCryst Pharmaceuticals in Q3 2013 and held it in 4 quarters.
  • Bridgeway Capital Management's BioCryst Pharmaceuticals position peaked at $418K in Q2 2014.
  • 102 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2014.

Based on Bridgeway Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.